PTGS2 and neoplasm: The expression of PTGS2, which drives inflammation and tumor-promoting PGE2 production (25, 34–36), shifted modestly toward the healthy range after AHR agonist treatment (most visibly with Carbidopa) but did not fully normalize, whereas PGE2 changes did not reach statistical significance.